Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
10/2004
10/28/2004CA2521109A1 Anti-tumor vasculature effects of human serum albumin derivatives
10/28/2004CA2520970A1 Hemophilia treatment by inhalation of coagulation factors
10/28/2004CA2520255A1 Tie-2 modulators and methods of use
10/28/2004CA2517926A1 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
10/28/2004CA2517154A1 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
10/27/2004EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
10/27/2004EP1470109A1 Metabolites of (3- [(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl -phenoxy)-acetic acid
10/27/2004EP1089984B1 Non-yellowing para-tertiary-alkyl phenyl substituted triazine and pyrimidine ultraviolet light absorbers
10/27/2004EP1079860B1 Nicotine immunogen
10/27/2004CN1541225A Humanized antibodies that recognize beta amyloid peptide
10/27/2004CN1541215A HIV inhibiting pyrimidines derivatives
10/26/2004CA2418634C Pharmaceutical compositions of tizoxanide and nitazoxanide
10/21/2004WO2004089940A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
10/21/2004WO2004089313A2 Novel olanzapine forms and related methods of treatment
10/21/2004WO2004089312A2 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
10/21/2004WO2004089311A2 Polymeric drug agents for the treatment of fibrotic disorders
10/21/2004WO2004089309A2 Conposition and methods for inhibiting fungal growth and transference
10/21/2004WO2004089308A2 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
10/21/2004WO2004089305A2 Heparin/heparosan synthase from p.multocida, soluble and single action catalysts thereof and methods of making and using same
10/21/2004WO2004089304A2 Antiandrogens with marginal agonist activity and methods of use
10/21/2004WO2004089303A2 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
10/21/2004WO2004089302A2 Posh polypeptides, complexes and related methods
10/21/2004WO2004089301A2 Compositions, splice variants and methods relating to colon specific genes and proteins
10/21/2004WO2004089300A2 Sapphyrins and uses thereof
10/21/2004WO2004089299A2 Pulsatile transdermally administered antigens and adjuvants
10/21/2004WO2004089297A2 Compounds and methods for treatment of thrombosis
10/21/2004WO2004089296A2 Improved inhibitors for the soluble epoxide hydrolase
10/21/2004WO2004089295A2 Homogeneous and heterogeneous assay methods using nucleation centers and novel covalent chemistries for the rapid measurement of phosphorylation and de-phosphorylation
10/21/2004WO2004089294A2 Compositions, methods and kits relating to her-2 cleavage
10/21/2004WO2004089293A2 Hydroxamic acid compounds and methods of use thereof
10/21/2004WO2004089292A2 Immunomodulatory agents for treatment of inflammatory diseases
10/21/2004WO2004089291A2 Tumor-targeting drug-loaded particles
10/21/2004WO2004089290A2 Novel probiotic compositions and methods of using the same
10/21/2004WO2004089289A2 Treating or preventing hot flashes using prodrugs of gaba analogs
10/21/2004WO2004089287A2 Spray dry coacervation systems and methods
10/21/2004WO2004089286A2 Novel compounds and compositions as protein kinase inhibitors
10/21/2004WO2004089285A2 Phosphodiesterase 2a and methods of use
10/21/2004WO2004089284A2 Targets for tumor growth inhibition
10/21/2004WO2004089283A2 Compositions and methods for treating viral infections
10/21/2004WO2004089282A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/21/2004WO2004089281A2 Novel polymorphs of tolterodine tartrate
10/21/2004WO2004089280A2 Reversible pegylated drugs
10/21/2004WO2004089279A2 Long-acting derivatives of pyy agonists
10/21/2004WO2004089278A2 Sexual hygienic composition
10/21/2004WO2004080380A3 Use of catechuic polyphenols for preparing compositions for stimulating a skin's natural pigmentation
10/21/2004WO2004073592A3 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier
10/21/2004WO2004069180A3 Solid dispersion compositions
10/21/2004WO2004069137A3 Use of polyamino and/or polyammonium-polysiloxane copolymers
10/21/2004WO2004058144A3 Antibacterial agents
10/21/2004WO2004054506A3 Methods and compositions for modulating nf-at transcription factor
10/21/2004WO2004050029A3 Novel activated polyethylene glycol compounds
10/21/2004WO2004047765A3 Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass
10/21/2004WO2004043369A3 Sulfonamides
10/21/2004WO2004037189A3 Methods for vaccinating against malaria
10/21/2004WO2004037186A3 Prophylactic treatment methods
10/21/2004WO2004037181A3 Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
10/21/2004WO2004034971A3 Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
10/21/2004WO2004016223A3 Assaying compounds or agents for microsomal prostaglandin e synthase or hematopoietic prostaglandin d synthase activity
10/21/2004WO2004009776A3 TREATMENT OF TNFα RELATED DISORDERS
10/21/2004WO2004009032A3 Method and composition for treating and preventing hepatitis b infection and symptoms thereof
10/21/2004WO2003096980A3 Bicyclic modulators of androgen receptor function
10/21/2004US20040210037 Comprises major histocompatibility complex fusion protein for use in treating and/or preventing cancer, infection, allergies and autoimmune diseases
10/21/2004US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
10/21/2004US20040209922 Pyridine matrix metalloproteinase inhibitors
10/21/2004US20040209836 activation of antigen-presenting cells; modifying dendritic cells to express an inducible form of a co-stimulatory polypeptide molecule; used to bolster the immune response of an immunocompromised subject, such as an HIV-infected subject
10/21/2004US20040209812 Use of erythropoietin in stroke recovery
10/21/2004US20040209804 comprises calcium for stable, extendend release; improved bioavailability; protamines; for treatment of turner's syndrome, crohn's disease, burns
10/21/2004US20040209801 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; kits
10/21/2004US20040209316 Methods and compositions related to joint inflammation diseases
10/21/2004US20040209310 Ligands that bind to the amyloid-beta precursor peptide and related molecules and uses thereof
10/21/2004US20040208931 Fast dissolving films for oral administration of drugs
10/21/2004US20040208893 Seaweed extract composition for treatment of diabetes and diabetic complications
10/21/2004US20040208865 Immune complexes
10/21/2004US20040208863 Anti-inflammatory activity from lactic acid bacteria
10/21/2004CA2843439A1 Reversible pegylated drugs
10/21/2004CA2522023A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
10/21/2004CA2521855A1 Feminine hygiene composition comprising an equid milk extract
10/21/2004CA2521407A1 Polymeric drug agents for the treatment of fibrotic disorders
10/21/2004CA2521399A1 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
10/21/2004CA2521184A1 Novel compounds and compositions as protein kinase inhibitors
10/21/2004CA2520987A1 Targets for tumor growth inhibition
10/21/2004CA2520870A1 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
10/21/2004CA2520867A1 Pulsatile transdermally administered antigens and adjuvants
10/21/2004CA2520866A1 Phosphodiesterase 2a and methods of use
10/21/2004CA2520763A1 Improved inhibitors for the soluble epoxide hydrolase
10/21/2004CA2520611A1 Hydroxamic acid compounds and methods of use thereof
10/21/2004CA2520468A1 Treating or preventing hot flashes using prodrugs of gaba analogs
10/21/2004CA2520452A1 Sapphyrins and uses thereof
10/21/2004CA2519927A1 Novel probiotic compositions and methods of using the same
10/21/2004CA2517833A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
10/20/2004EP1468689A1 2-methyl-thieno-benzodiazepine formulation
10/20/2004EP1468687A1 Compounds for the treatment of cancer
10/20/2004EP1468686A2 S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
10/20/2004EP1468679A2 Controlled release formulation containing tramadol
10/20/2004EP1467745A2 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders
10/20/2004EP1467731A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
10/20/2004EP1230236B1 Compound with growth hormone releasing properties
10/20/2004EP1206473B1 Isomeric fused pyrrolocarbazoles and isoindolones
10/20/2004EP1194115B1 Topically applied idebenone-containing agent with protective and regenerative effect
10/20/2004EP1149074B1 Acetylenic sulfonamide thiol tace inhibitors
1 ... 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 ... 295